About Clementia
Clementia is a company based in Dorval (Canada) founded in 2012 was acquired by Ipsen in February 2019. Clementia has raised $92.5 million across 5 funding rounds from investors including UCB, Ipsen and Orbimed. Clementia offers products and services including Oncology Medicines, Rare Disease Treatments, and Neuroscience Products. Clementia operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Mereo BioPharma and Amicus Therapeutics, among others.
- Headquarter Dorval, Canada
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Ipsen Pharma
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Clementia
Clementia offers a comprehensive portfolio of products and services, including Oncology Medicines, Rare Disease Treatments, and Neuroscience Products.
Treatments for cancers and tumors in oncology field
Therapies for rare genetic and liver disorders
Medications for debilitating neurological conditions
People of Clementia
Unlock access to complete
Unlock access to complete
Leadership Team
165 people
Software Development Team
160 people
Product Management Team
44 people
Human Resources and Administration
41 people
Finance and Accounting
36 people
Senior Team
32 people
Sales and Marketing
30 people
Operations Team
29 people
Unlock access to complete
Funding Insights of Clementia
Clementia has successfully raised a total of $92.5M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $60 million completed in July 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Clementia
Clementia has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include UCB, Ipsen and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are offered to startups by NEA.
|
Locked | Locked | Locked | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
Multiple sectors are targeted for venture capital investments.
|
Locked | Locked | Locked |
Investor details for Clementia
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Clementia
Investment portfolio details for Clementia
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Clementia
Detailed financials for Clementia
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Clementia Comparisons
Peer comparison for Clementia
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Clementia
Clementia operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Mereo BioPharma and Amicus Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of therapies for rare and orphan diseases
|
|
| Locked | Locked | Locked |
Developer of therapeutics to treat rare genetic diseases
|
Detailed competitors of Clementia
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Clementia
Complete news archive for Clementia
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Clementia
Clementia was founded in 2012.
Clementia is headquartered in Dorval, Canada. It is registered at Dorval, Quebec, Canada.
David Loew is the current CEO of Clementia.
Clementia is a funded company, having raised a total of $92.5M across 5 funding rounds to date.
Clementia was founded in 2012 in Dorval, Canada, within the biotechnology sector focused on rare diseases. Treatments for conditions like Fibrodysplasia Ossificans Progressiva are advanced through retinoic acid receptor gamma science. The lead candidate, Palovarotene, is investigated as an agonist to inhibit abnormal bone growth. Orphan Drug Designation was granted by the FDA in 2014, and Orphan Medicinal Product Designation was received from the EMA.
Clementia's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Clementia offers Oncology Medicines, Rare Disease Treatments, and Neuroscience Products.
Clementia has 9 investors. Key investors include UCB, Ipsen, Orbimed, Janus Henderson Investors, and RA Capital.